Background： Najanalgesin, a toxin isolated from the venom ofNaja nqja atra, has been shown to exert significant analgesic effects in a neuropathic pain model in rats. However, the molecular mechanism underlying this ...Background： Najanalgesin, a toxin isolated from the venom ofNaja nqja atra, has been shown to exert significant analgesic effects in a neuropathic pain model in rats. However, the molecular mechanism underlying this protective effect ofnajanalgesin is poorly understood. The present study sought to evaluate the intracellular signaling pathways that are involved in the antinociceptive effect of najanalgesin on neuropathic pain. Methods： The antinociceptive properties of najanalgesin were tested in hind paw withdrawal thresholds in response to mechanical stimulation. We analyzed the participation of the mitogen-activated protein kinase p38, extracellular-regulated kinase （ERK）, and c-Jun N-terminal kinase （JNK） by western blot analysis. This inhibition of JNK was confirmed by immunohistochemistry. Results： The phosphorylation levels of INK （as well as its downstream molecule c-Jun）, p38, and ERK were significantly increased after injury. Najanalgesin only inhibited JNK and c-Jun phosphorylation but had no effect on either ERK or p38. This inhibition of JNK was confirmed by immunohistochemistry, which suggested that the antinociceptive effect of najanalgesin on spinal nerve ligation-induced neuropathic pain in rats is associated with JNK activation in the spinal cord. Conclusion： The antinociceptive effect of najanalgesin thnctions by inhibiting the JNK in a neuropathic pain model.展开更多
基金This study was supported by the grants from the National Natural Science Foundation of China，the Shandong Province National Natural Science Foundation，the project from Weifang Science and Technology Bureau，the Weifang Medical Technology Innovation Project
文摘Background： Najanalgesin, a toxin isolated from the venom ofNaja nqja atra, has been shown to exert significant analgesic effects in a neuropathic pain model in rats. However, the molecular mechanism underlying this protective effect ofnajanalgesin is poorly understood. The present study sought to evaluate the intracellular signaling pathways that are involved in the antinociceptive effect of najanalgesin on neuropathic pain. Methods： The antinociceptive properties of najanalgesin were tested in hind paw withdrawal thresholds in response to mechanical stimulation. We analyzed the participation of the mitogen-activated protein kinase p38, extracellular-regulated kinase （ERK）, and c-Jun N-terminal kinase （JNK） by western blot analysis. This inhibition of JNK was confirmed by immunohistochemistry. Results： The phosphorylation levels of INK （as well as its downstream molecule c-Jun）, p38, and ERK were significantly increased after injury. Najanalgesin only inhibited JNK and c-Jun phosphorylation but had no effect on either ERK or p38. This inhibition of JNK was confirmed by immunohistochemistry, which suggested that the antinociceptive effect of najanalgesin on spinal nerve ligation-induced neuropathic pain in rats is associated with JNK activation in the spinal cord. Conclusion： The antinociceptive effect of najanalgesin thnctions by inhibiting the JNK in a neuropathic pain model.
